RNS Reach - non-regulatory announcement

30 January 2025

Solvonis Therapeutics plc
("Solvonis Therapeutics" or the "Company")

Proactive Investors interview with Chairman

Solvonis Therapeutics (LON: SVNS), an innovative biotechnology company co-developing therapeutics for mental health disorders, announces that Dennis Purcell, Chairman of the Company, has recently given an interview to Proactive Investors about the increasing mergers and acquisitions activity in the neuroscience sector. The interview can be viewed at https://www.proactiveinvestors.co.uk/companies/news/1065372/solvonis-therapeutics-chairman-on-the-future-of-biotech-neuroscience-ma.html.

Enquiries:

Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
Email: anthony@solvonis.com

Allenby Capital (Financial Adviser and Broker) +44 (0) 20 3328 5656

Nick Naylor / Liz Kirchner (Corporate Finance) | Guy McDougall (Sales)

About Solvonis Therapeutics plc

Solvonis Therapeutics plc is an innovative biotechnology company focused on developing intellectual property related to the treatment of mental health and substance use disorders, and co-developing therapeutics for mental health disorders. Solvonis' mission is to improve outcomes for individuals suffering from mental health disorders, with an initial focus on trauma-related mental health conditions, such as PTSD. PTSD affected approximately 13 million adults in the U.S. in 2020, with the Company estimating a current affected population of 20 million across the U.S., UK, and key EU markets.

www.solvonis.com | LinkedIn | X (formerly Twitter) 

About Reach announcements

This is an RNS Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain.  Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.